B-cell and T-cell activation in South African HIV-1-positive non-Hodgkin’s lymphoma patients
dc.contributor.author | Flepisi, Brian T. | en_ZA |
dc.contributor.author | Bouic, Patrick | en_ZA |
dc.contributor.author | Sissolak, Gerhard | en_ZA |
dc.contributor.author | Rosenkranz, Bernd | en_ZA |
dc.date.accessioned | 2020-02-10T09:57:41Z | |
dc.date.available | 2020-02-10T09:57:41Z | |
dc.date.issued | 2018 | |
dc.description | CITATION: Flepisi, B. T., et al. 2018. B-cell and T-cell activation in South African HIV-1-positive non-Hodgkin’s lymphoma patients. Southern African Journal of HIV Medicine, 19(1):a809, doi:10.4102/sajhivmed.v19i1.809. | |
dc.description | The original publication is available at https://sajhivmed.org.za | |
dc.description.abstract | Background: Altered immune mechanisms play a critical role in the pathogenesis of non-Hodgkin’s lymphoma (NHL). HIV-1 (HIV) infection is associated with a state of excessive T-cell activation, which can lead to increased T-cell turnover and lymph node fibrosis. Objectives: This study aimed to determine the serum levels of circulating B-cell activation markers, and the expression of T-cell activation and regulatory markers in HIV-positive NHL patients. Method: The serum levels of circulating soluble(s) sCD20, sCD23, sCD27, sCD30 and sCD44 molecules, all of which are biomarkers of B-cell activation, were determined by enzyme-linked immunosorbent assays (ELISA), while biomarkers of T-cell activation (CD8+CD38+) and regulation (FoxP3) were determined by flow cytometry in 141 subjects who were divided into five groups: Combination antiretroviral therapy (ART)-naïve HIV-positive patients; ART-treated HIV-positive patients; HIV-negative NHL patients; HIV-positive NHL patients on ART; and healthy controls. Results: HIV-positive NHL patients had significantly higher serum levels of sCD20, sCD23, sCD30 and sCD44 than HIV-negative NHL patients, while all five biomarkers were significantly elevated in HIV-positive NHL patients when compared with ART-treated HIV-positive patients. HIV-positive NHL patients had higher CD8+CD38+ and lower FoxP3 expression than HIV-negative NHL and ART-treated HIV-positive patients. Conclusion: B-cell activation is increased in HIV-positive NHL patients and is associated with reduced regulatory T-cell populations and increased CD8+ T-cell activation. | en_ZA |
dc.description.uri | https://sajhivmed.org.za/index.php/HIVMED/article/view/809 | |
dc.description.version | Publisher's version | |
dc.format.extent | 7 pages | |
dc.identifier.citation | Flepisi, B. T., et al. 2018. B-cell and T-cell activation in South African HIV-1-positive non-Hodgkin’s lymphoma patients. Southern African Journal of HIV Medicine, 19(1):a809, doi:10.4102/sajhivmed.v19i1.809 | |
dc.identifier.issn | 2078-6751 (online) | |
dc.identifier.issn | 1608-9693 (print) | |
dc.identifier.other | doi:10.4102/sajhivmed.v19i1.809 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/107460 | |
dc.language.iso | en_ZA | en_ZA |
dc.publisher | Medpharm Publications | |
dc.rights.holder | Authors retain copyright | |
dc.subject | HIV-positive persons -- South Africa | en_ZA |
dc.subject | HIV (Viruses) -- Analysis | en_ZA |
dc.subject | B cells -- Mechanism of action | en_ZA |
dc.subject | T cells -- Mechanism of action | en_ZA |
dc.subject | Cell interaction -- Immunology | en_ZA |
dc.subject | Lymphomas -- Patients -- South Africa | en_ZA |
dc.subject | Non-Hodgkin’s lymphoma -- Infections | en_ZA |
dc.title | B-cell and T-cell activation in South African HIV-1-positive non-Hodgkin’s lymphoma patients | en_ZA |
dc.type | Article | en_ZA |